Ultragenyx Pharmaceutical Inc. (RARE) Revenue Growth
Ultragenyx Pharmaceutical Inc. (RARE) year-over-year revenue growth rate history. Analyze revenue growth in Excel with MarketXLS.
Revenue Growth Data
| Period | YoY Revenue Growth |
|---|---|
| 2017-12-31 | 1863.91% |
| 2018-12-31 | 1871.48% |
| 2019-12-31 | 101.41% |
| 2020-12-31 | 161.32% |
| 2021-12-31 | 29.66% |
| 2022-12-31 | 3.39% |
| 2023-12-31 | 19.52% |
| 2024-12-31 | 28.96% |
| 2025-12-31 | 20.18% |
How RARE compares with sector peers
| Symbol | Company | Revenue growth (latest fiscal year) |
|---|---|---|
| NBIX | Neurocrine Biosciences Inc. | 21.45% |
| INCY | Incyte Corporation | 21.22% |
| AXGN | Axogen Inc. | 20.21% |
| ENSG | The Ensign Group Inc. | 18.72% |
| TFX | Teleflex Incorporated | 17.25% |
These are five companies in the same sector as RARE with a comparable annual revenue growth. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Ultragenyx Pharmaceutical Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue_Growth("RARE", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | RARE | $14.85 | -44.03% | 15.66M |
| 3 | ||||
| 4 | ||||
| 5 |